Regeneron Pharmaceuticals (NASDAQ:REGN) and the University of Oxford announce that RECOVERY (Randomised Evaluation of COVID-19 Therapy), will evaluate Regeneron’s investigational anti-viral antibody cocktail, REGN-COV2.
The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.
Other endpoints include the impact on hospital stay and the need for ventilation. It is anticipated that at least 2,000 patients will be enrolled in the study.
The inclusion of convalescent plasma in the RECOVERY trial was announced in June. The trial will compare adding convalescent plasma to usual standard-of-care versus standard-of-care on its own.
An Independent Data Monitoring Committee is monitoring all Regeneron-led REGN-COV2 Phase 2 and 3 trials, and all trials continue to enroll patients.
REGN-COV2 comprises two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.